Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Y. Chen"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 204
Tytuł:
A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy.
Autorzy:
Zhao Y; The First Hospital of Jilin University, Changchun, China.
Chen X; The First Hospital of Jilin University, Changchun, China.
Yao J; The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Long J; Chongqing University Affiliated Cancer Hospital, Chongqing, China.
Mao Y; Affiliated Hospital of Jiangnan University, Wuxi, China.
Wu D; The First Hospital of Jilin University, Changchun, China.
Zang A; Affiliated Hospital of Hebei University, Baoding, China.
Zhao J; Beijing Cancer Hospital, Beijing, China.
Liu Z; The First Hospital of Jilin University, Changchun, China.
Meng R; Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Chen Y; Innovent Biologics, Inc., Suzhou, China.
Luo Y; Innovent Biologics, Inc., Suzhou, China.
Guo Q; Innovent Biologics, Inc., Suzhou, China.
Li L; Innovent Biologics, Inc., Suzhou, China.
Cui J; The First Hospital of Jilin University, Changchun, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 Feb; Vol. 13 (3), pp. e6855. Date of Electronic Publication: 2024 Jan 12.
Typ publikacji:
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Agents*
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cinchonine and cinchonidine alleviate cisplatin-induced ototoxicity by regulating PI3K-AKT signaling.
Autorzy:
Tang D; ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.
Wang X; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
Wu J; ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.
Li Y; ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.
Li C; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
Qiao X; Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Fan L; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
Chen Y; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhu H; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
Zhang Z; Department of Otorhinolaryngology-Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, China.
He Y; ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, NHC Key Laboratory of Hearing Medicine, Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Feb; Vol. 30 (2), pp. e14403. Date of Electronic Publication: 2023 Aug 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/toxicity
Ototoxicity*/drug therapy
Cinchona Alkaloids*/pharmacology
Mice ; Animals ; Cisplatin/toxicity ; Proto-Oncogene Proteins c-akt/metabolism ; Caspase 3/metabolism ; Phosphatidylinositol 3-Kinases ; Reactive Oxygen Species/metabolism ; Molecular Docking Simulation ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
Autorzy:
Chen Y; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
Ma F; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California, USA.
Jones N; Clinical Science, Genentech, Inc., South San Francisco, California, USA.
Deng R; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li C; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li CC; Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Feb; Vol. 13 (2), pp. 234-246. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Journal Article
MeSH Terms:
Cytochrome P-450 CYP3A*/metabolism
Antineoplastic Agents*
Humans ; Interleukin-6 ; Cytokines ; Drug Interactions ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Models, Biological
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies.
Autorzy:
Yu X; State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Haikou, China. .; Key Laboratory of Biomedical Engineering of Hainan Province, One Health Institute, Hainan University, Haikou, China. .
Jia S; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.; The First College of Clinical Medical Science, China Three Gorges University, Yichang, China.
Yu S; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Chen Y; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Zhang C; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Chen H; The First College of Clinical Medical Science, China Three Gorges University, Yichang, China. .
Dai Y; State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Haikou, China. .; Key Laboratory of Biomedical Engineering of Hainan Province, One Health Institute, Hainan University, Haikou, China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2023 Nov 28; Vol. 21 (1), pp. 454. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents*/chemistry
Neoplasms*/drug therapy
Nanoparticles*/chemistry
Humans ; Melitten/pharmacology ; Melitten/chemistry ; Melitten/therapeutic use ; Peptides/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Amino Acid Derivatives of Ginsenoside AD-2 Induce HepG2 Cell Apoptosis by Affecting the Cytoskeleton.
Autorzy:
Lin L; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhao Y; Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, China.
Wang P; ORxes Therapeutics (Shanghai) Co., Ltd., Shanghai 200000, China.
Li T; Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji 133002, China.
Liang Y; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Chen Y; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Meng X; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhang Y; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.
Su G; School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China.; Key Laboratory of Innovative Traditional Chinese Medicine for Major Chronic Diseases of Liaoning Province, Shenyang 110016, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Nov 02; Vol. 28 (21). Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Ginsenosides*/pharmacology
Ginsenosides*/chemistry
Antineoplastic Agents*/pharmacology
Humans ; Hep G2 Cells ; Caspase 3/metabolism ; Cell Line, Tumor ; Apoptosis ; Cytoskeleton/metabolism ; Amino Acids/pharmacology ; Cell Proliferation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Autorzy:
Lv X; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Lu X; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Cao J; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Luo Q; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Ding Y; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Peng F; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Pataer A; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lu D; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030, USA.
Han D; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Malmberg E; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Chan DW; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Wang X; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Savage SR; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Mao S; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Yu J; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Peng F; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA.
Yan L; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Meng H; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Maneix L; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Huffington Center on Aging, Baylor College of Medicine, USA.
Han Y; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Chen Y; Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yao W; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chang EC; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Catic A; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Huffington Center on Aging, Baylor College of Medicine, USA.
Lin X; Division of Surgical Oncology, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Miles G; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Huang P; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Sun Z; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA.
Burt B; Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Wang H; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wang J; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030, USA.
Yao QC; Division of Surgical Oncology, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Zhang B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Roth JA; Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
O'Malley BW; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Ellis MJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.; Early Oncology, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Rimawi MF; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Ying H; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chen X; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2023 Sep 08; Vol. 381 (6662), pp. eabn4180. Date of Electronic Publication: 2023 Sep 08.
Typ publikacji:
Journal Article
MeSH Terms:
Endoribonucleases*
Extracellular Signal-Regulated MAP Kinases*
Neoplasms*/drug therapy
Neoplasms*/genetics
Proteostasis*
Proto-Oncogene Proteins p21(ras)*/antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)*/genetics
Drug Resistance, Neoplasm*
Enzyme Inhibitors*/pharmacology
Antineoplastic Agents*/pharmacology
Heat Shock Transcription Factors*/metabolism
Humans ; Protein Serine-Threonine Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8 T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer.
Autorzy:
Li P; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.; School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong, People's Republic of China.; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Zhou D; Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangdong, Guangzhou, People's Republic of China.
Chen D; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Cheng Y; Department of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Chen Y; School of Medicine, Sun Yat-Sen University, Shenzhen, Guangdong, People's Republic of China.
Lin Z; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Zhang X; Guangzhou Biosyngen Co., Ltd., Guangdong, People's Republic of China.
Huang Z; Guangzhou Biosyngen Co., Ltd., Guangdong, People's Republic of China.
Cai J; Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangdong, Guangzhou, People's Republic of China.
Huang W; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Lin Y; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Ke H; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Long J; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
Zou Y; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China. .; Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangdong, Guangzhou, People's Republic of China. .
Ye S; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China. .; Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangdong, Guangzhou, People's Republic of China. .; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. .
Lan P; Guangdong Institute of Gastroenterology; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China. .; Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangdong, Guangzhou, People's Republic of China. .; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. .; State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, People's Republic of China. .
Pokaż więcej
Źródło:
Journal of biomedical science [J Biomed Sci] 2023 Jun 28; Vol. 30 (1), pp. 47. Date of Electronic Publication: 2023 Jun 28.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*
Colonic Neoplasms*
Humans ; Animals ; Mice ; Phosphatidylinositol 3-Kinases ; Proto-Oncogene Proteins c-akt/genetics ; CD8-Positive T-Lymphocytes ; Proteomics ; Signal Transduction ; TOR Serine-Threonine Kinases/genetics ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance.
Autorzy:
He P; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Xu S; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Miao Z; School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, Anhui, China.
Que Y; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Chen Y; Department of Pharmacy, Anqing Medical College, Anqing, 246052, Anhui, China.
Li S; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Ma Q; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Yang R; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Wei W; Institute of Clinical Pharmacology, Anhui Medical University, Hefei, 230032, Anhui, China. .
Zha Z; School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, Anhui, China. .
Hu Y; Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2023 Jun 27; Vol. 21 (1), pp. 203. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Ferroptosis*
Osteosarcoma*/drug therapy
Bone Neoplasms*/drug therapy
Humans ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Reactive Oxygen Species/metabolism ; Glutathione/metabolism ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.
Autorzy:
Han Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Pan Q; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Guo Z; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.; Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Du Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Zhang Y; Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Liu Y; Department of Ultrasonography, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Clinical Medical College of Southern University of Science and Technology, Shenzhen, Guangdong, P. R. China.
Zhao J; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Xu J; Department of Ultrasonography, Shenzhen Medical Ultrasound Engineering Center, Shenzhen People's Hospital, Second Clinical Medical College of Jinan University, First Clinical Medical College of Southern University of Science and Technology, Shenzhen, Guangdong, P. R. China.
Yang J; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Ouyang D; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Tang Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Wang Q; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Li Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
He J; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Yang M; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Chen H; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Yang C; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Yang X; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
You J; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Chen Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Ren M; Application Business Division, Shandong Qilu Stem Cell Engineering Co., Ltd., Shandong, Guangdong, P. R. China.
Zhu Y; Department of Materials Science, Shenzhen MSU-BIT University, Shenzhen, Guangdong, P. R. China.
Xia J; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Xiang T; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 May; Vol. 13 (5), pp. e1247.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/drug therapy
Hepatitis B*/complications
Liver Neoplasms*/therapy
Liver Neoplasms*/drug therapy
Animals ; Humans ; Mice ; B7-H1 Antigen ; Bone Morphogenetic Proteins/therapeutic use ; Hepatitis B virus/genetics ; Immunotherapy/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.
Autorzy:
Pan M; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Sha Y; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.; The First Clinical Medical Institute, Henan University of Chinese Medicine, Zhengzhou 450000, China.
Qiu J; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Chen Y; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Liu L; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Luo M; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Huang A; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Xia J; Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, Chongqing 400016, China.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 26; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Rad51 Recombinase/genetics ; Cell Line, Tumor ; Cell Proliferation ; Apoptosis ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
Autorzy:
Shi P; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Cheng Z; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhao K; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Chen Y; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang A; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Gan W; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang Y; Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2023 Mar 22; Vol. 21 (1), pp. 103. Date of Electronic Publication: 2023 Mar 22.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Osteosarcoma*/drug therapy
Bone Neoplasms*/drug therapy
Nanoparticles*
Humans ; Nanoparticle Drug Delivery System ; Ligands ; Drug Carriers/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
DROEG: a method for cancer drug response prediction based on omics and essential genes integration.
Autorzy:
Wu P; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Sun R; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; CAS Key Laboratory of Computational Biology, Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Fahira A; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Chen Y; School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai, China.
Jiangzhou H; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Wang K; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Yang Q; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Dai Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Pan D; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Shi Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Wang Z; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.; Collaborative Innovation Centre for Brain Science, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło:
Briefings in bioinformatics [Brief Bioinform] 2023 Mar 19; Vol. 24 (2).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Neoplasms*/drug therapy
Neoplasms*/genetics
Humans ; Genes, Essential ; Genomics/methods ; Precision Medicine/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Autorzy:
Chen Y; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang X; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Du F; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yue J; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Si Y; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhao X; The Medical Department, 3D Medicines Inc., Shanghai 201114, China.
Cui L; The Medical Department, 3D Medicines Inc., Shanghai 201114, China.
Zhang B; The Medical Department, 3D Medicines Inc., Shanghai 201114, China.
Bei T; The Medical Department, 3D Medicines Inc., Shanghai 201114, China.
Xu B; Department of Medical Oncology and Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Cancer biology & medicine [Cancer Biol Med] 2023 Mar 02; Vol. 20 (2).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Homologous Recombination*
Triple Negative Breast Neoplasms*/drug therapy
Triple Negative Breast Neoplasms*/genetics
Platinum*/therapeutic use
Antineoplastic Agents*/therapeutic use
Humans ; Adjuvants, Immunologic ; Retrospective Studies ; East Asian People
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Autorzy:
Pan Z; Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, China.
Luo Z; Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, China.
He H; Department of Obstetrics and Gynecology, Liuzhou Workers Hospital, Liuzhou, China.
Chen Y; Department of Obstetrics and Gynecology, Liuzhou People's Hospital, Liuzhou, China.
Zhao B; Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, China.
Yang Z; Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, China.
Li L; Department of Gynecology and Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, China. .
Pokaż więcej
Źródło:
Journal of ovarian research [J Ovarian Res] 2023 Feb 23; Vol. 16 (1), pp. 44. Date of Electronic Publication: 2023 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Ovarian Neoplasms*/drug therapy
Female ; Humans ; Carcinoma, Ovarian Epithelial/drug therapy ; Platinum/pharmacology ; Platinum/therapeutic use ; Retrospective Studies ; Vascular Endothelial Growth Factor A ; Drug Resistance, Neoplasm
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities.
Autorzy:
Tang L; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Zhang Y; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Xu J; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Yang Q; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou 646000, China.
Du F; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Wu X; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Li M; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Shen J; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Deng S; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Zhao Y; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Xiao Z; Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Chen Y; Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.; Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Feb 02; Vol. 28 (3). Date of Electronic Publication: 2023 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Oleanolic Acid*
Antineoplastic Agents*/pharmacology
Humans ; Molecular Structure ; Structure-Activity Relationship ; HeLa Cells ; Drug Screening Assays, Antitumor ; Cell Proliferation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.
Autorzy:
Qiu H; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Ke S; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Cai G; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Wu Y; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Wang J; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Shi W; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Chen J; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Peng J; Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yu B; Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.
Chen Y; Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jan; Vol. 12 (1), pp. 213-222. Date of Electronic Publication: 2022 May 27.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/adverse effects
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/radiotherapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/radiotherapy
Radiotherapy, Intensity-Modulated*/adverse effects
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
Autorzy:
He K; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Yang Z; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Liu X; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Yang Y; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Song W; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Wang S; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Chen Y; Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 29; Vol. 30 (1), pp. 476-491. Date of Electronic Publication: 2022 Dec 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Antineoplastic Agents*/therapeutic use
Liver Neoplasms*/drug therapy
Chemoembolization, Therapeutic*/adverse effects
Chemoembolization, Therapeutic*/methods
Humans ; Sorafenib/therapeutic use ; Vascular Endothelial Growth Factor A/therapeutic use ; Retrospective Studies ; Niacinamide/therapeutic use ; Niacinamide/adverse effects ; Phenylurea Compounds/therapeutic use ; Phenylurea Compounds/adverse effects ; Treatment Outcome ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
Autorzy:
Liu J; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yin R; Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.; Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth Defects of the Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
Wu L; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zhu J; Department of Gynecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Lou G; Department of Gynecology Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Wu X; Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhou Q; Chongqing Cancer Hospital, Chongqing, China.
Gao Y; Beijing Cancer Hospital, Beijing, China.
Kong B; Qilu Hospital of Shandong University, Jinan, China.
Lu X; Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Wang J; Hunan Cancer Hospital, Changsha, China.
Chen Y; The First Affiliated Hospital of Soochow University, Suzhou, China.
Cheng Y; Jilin Cancer Hospital, Changchun, China.
Wang Y; No. 1 Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, China.
Lu W; Women's Hospital School of Medicine, Zhejiang University, Hangzhou, China.
Li W; Oncology Center, The First Hospital of Jilin University, Changchun, China.
Ma X; AstraZeneca, Shanghai, China.
Hsu K; Celgene, San Diego, California, USA.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Dec; Vol. 18 (6), pp. 714-722. Date of Electronic Publication: 2022 Mar 31.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/genetics
Female ; Humans ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/genetics ; Maintenance Chemotherapy ; Neoplasm Recurrence, Local/drug therapy ; Phthalazines/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.
Autorzy:
Chen Y; Affiliated Hospital of Jiangnan University, Wuxi214000, Jiangsu Province, China.
Xu Z; Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi214000, Jiangsu Province, China.
Lu T; Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi214000, Jiangsu Province, China.
Luo J; Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong226000, Jiangsu Province, China.
Xue H; Department of Pharmacy, Wuxi Mental Health Center, Wuxi214000, Jiangsu Province, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 2705-2712.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*
Nanoparticles*
Prostatic Neoplasms*/drug therapy
Animals ; Benzamides ; Cell Line, Tumor ; Cystamine/therapeutic use ; Docetaxel ; Glutathione ; Humans ; Ligands ; Male ; Mice ; Nitriles ; Phenylthiohydantoin ; Polyethylene Glycols/therapeutic use ; Prostate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Autorzy:
Zhou H; Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yin Q; Henan Cancer Hospital, Zhengzhou, China.
Jin J; The First Affiliated Hospital, College of Medicine, Zhejiang University College of Medicine, Hangzhou, China.
Liu T; West China Hospital, Sichuan University, Chengdu, China.
Cai Z; The First Affiliated Hospital, College of Medicine, Zhejiang University College of Medicine, Hangzhou, China.
Jiang B; Peking University International Hospital, Beijing, China.
Li D; Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
Sun Z; Anhui Provincial Hospital, Hefei, China.
Li Y; The First Hospital of China Medical University, Shenyang, China.
He Y; Xiangya Hospital Central South University, Changsha, China.
Ma L; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Gao S; The First Hospital of Jilin University, Jilin, China.
Hu J; Fujian Medical University Union Hospital, Fujian, China.
He A; The Second Affiliated Hospital of Xian Jiaotong University, Shaanxi, China.
Du X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Liu D; Chinese People Liberation Army General Hospital, Beijing, China.
Zhang X; The Second Affiliated Hospital Zhejiang University College of Medicine, Zhejiang, China.
Ke X; Peking University Third Hospital, Beijing, China.
Zhuang J; Peking Union Medical College Hospital, Beijing, China.
Han Y; The First Affiliated Hospital of Soochow University, Jiangsu, China.
Wang X; Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Chen Y; Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA.
Gordon P; Global Development, Amgen Inc., Thousand Oaks, CA, USA.
Yu D; Amgen China, Shanghai, People's Republic of China.
Zugmaier G; Global Development, Amgen Research (Munich) GmbH, Munich, Germany.
Wang J; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 917-927.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antibodies, Bispecific*/adverse effects
Antineoplastic Agents*/therapeutic use
Lymphoma, B-Cell*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Acute Disease ; Adult ; Child ; China ; Female ; Humans ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 204

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies